Bernard Gilly, Ph.D., CEO, Gensight Biologics (GSGTF)
Bernard Gilly, Ph.D., one of GenSight Biologics’ founders, has served as the Chief Executive Officer of the company since its creation.
From creation through to 2016, Dr. Gilly served as Chairman of the board of directors. From 2011 through 2014, he served as Chief Executive Officer at Pixium Vision, during which time he also served as non-executive Chairman of the board of directors.
In addition, he currently serves on the boards of Prophesee S.A. (formerly Chronocam) and TISSIUM (formerly Gecko Biomedical).
From 2005 to 2009, he founded and was Chairman and Chief Executive Officer of Fovea Pharmaceuticals S.A., or Fovea, a privately funded biotech company, which was later acquired by Sanofi.
He then became Senior Vice President of the Ophthalmology Division of Sanofi and served in that role until March 2012. Prior to Fovea, Dr. Gilly was a partner at Sofinnova Partners S.A.S. from December 2000 to November 2005.
From January 1992 to October 2000, he was Chief Executive Officer of Transgene S.A., a company listed on the Nasdaq and the Nouveau Marche of Euronext Paris, France. Dr. Gilly received an engineering degree from Ecole Nationale d’Agronomie and a Ph.D. from Universite de Rennes.
In this 2,22o word interview, exclusively in the Wall Street Transcript, Dr. Bernard Gilly develops the investment thesis for GenSight Biologics.
“GenSight is a gene therapy company leveraging two technology platforms.
One is a technology that, for the first time ever, allows us to target mitochondrial diseases. And the second technology is much better known. This is a technology that has been used at the bench by neurobiologists since the early 2000s.
It’s called optogenetics, and we are the first one to bring this technology to patients in an attempt to restore their vision.
The very first product that we are developing is called LUMEVOQ. At the time of the last interview, I think it was still called GS010, but now it has a commercial name.
This product addresses a mitochondrial disease of the retina called Leber Hereditary Optic Neuropathy, LHON. Importantly, as LUMEVOQ has proven its efficacy in LHON, the underlying technology platform allows GenSight to potentially address a number of other mitochondrial diseases affecting the retina but also elsewhere in the central nervous system.
So we now have a technology that demonstrates the efficacy of LUMEVOQ and a technology that could apply to a wide range of other mitochondrial diseases.”
Dr. Bernard Gilly discusses the exciting development of European drug approval:
“We have completed three clinical trials — three pivotal trials, Phase III trials.
We have filed for approval in Europe, and we are expecting approval by the European Medicines Agency by the end of this year. We are now organizing the commercial infrastructure in Europe to launch the product very early in 2023.”
GenSight Biologics SA (GSGTF) has created hope for this devastating medical condition:
“One important thing is that with LUMEVOQ moving forward, we have launched a fairly large compassionate use program to allow patients who are affected by LHON and losing their sight to access LUMEVOQ treatment. In the U.S., we have an expanded access IND program, which is delivering really well. In December 2021, Dr. Sean Donahue presented remarkably positive results from eight patients taking part in the expanded access program at the American Academy of Ophthalmology Conference and similar results are being observed in Europe.
In France, we also have the capacity under this compassionate program to invoice the product to the hospital. And that’s an interesting benchmark for the pricing we may have after the approval. At this moment, we are pricing it at EUR700,000 per treatment, which is really important in terms of the future revenue of the company.”
Get the complete detail on all the recent drug development from GenSight Biologics SA (GSGTF) by reading the entire 2,22o word interview with Dr. Bernard Gilly, exclusively in the Wall Street Transcript.
Bernard Gilly, Ph.D., Co-Founder & CEO
GenSight Biologics
74, rue du Faubourg Saint-Antoine
75012 Paris
France
www.gensight-biologics.com
Bernard Gilly, Ph.D, Co-Founder of GenSight Biologics Discusses the Proprietary Genetic Therapy Cure for Blindness his Company is Developing
October 23, 2018
A Potential Cure for Sickle Cell Anemia from GlycoMimetics (NASDAQ:GLYC) and Pfizer (NYSE:PFE)
May 03, 2017
Sue Washer, President and CEO of Applied Genetic Technologies Corporation (AGTC) Discusses the Cure for Retinitis Pigmentosa
March 19, 2018
Robotic Surgical System Using Artificial Intelligence to Cure Baldness: Restoration Robotics, Inc. (NASDAQ:HAIR)
July 23, 2018
